OTC Manufacturers Less Likely To Face Inspection Under cGMP Pilot
This article was originally published in The Tan Sheet
Executive Summary
Manufacturing facilities that produce OTC drugs exclusively may not be inspected as often as plants that make prescription drugs under FDA's risk-based prioritization plan for inspections
You may also be interested in...
Industry Input Will Bolster Risk-Based Inspection Approach – FDA’s Ellsworth
FDA is "hoping" to use future facility inspections to compile data that will strengthen the "process risk" prong of its risk-based site selection model by gaining knowledge about quality systems currently in use by industry, according to New Jersey District Director Douglas Ellsworth
GMP Inspections Still A Risky Process For OTC Firms – Attorney
FDA's cGMP regulation revisions reflect the agency's increasing focus on compliance for OTC manufacturers, according to Scott Bass of the Washington, D.C. law firm Sidley, Austin, Brown & Wood
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC